Class 800/14 - Mammal

Subclass of Class 800 - Multicellular living organisms and unmodified parts thereof and related processes
Definition: Subject matter wherein the transgenic nonhuman animal
No. of patents: 255
Last issue date: 04/23/2013

«First «Previous 1 2 3 4 5 6 7 Next»Last»

Number	Title	Issue Date
7045676	Transgenic animals secreting proteins into milk A DNA sequence containing a gene encoding a protein, the gene being under the transcriptional control in the DNA sequence of a mammalian milk protein promoter which does not naturally control the transcription of the gene, such DNA sequence including DNA enabling se...	05/16/2006
7041870	Transgenic transchromosomal rodents for making human antibodies The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies. ...	05/09/2006
7038107	Elimination of endogenous porcine retrovirus Porcine nucleic acid sequences flanking potentially infectious porcine endogenous retroviral (PERV) insertion sites have been identified and isolated. The unique flanking sequences include porcine nucleic acid sequences that flank the 3′ end and porcine nucleic ac...	05/02/2006
7034201	Developmental animal model of temporal lobe epilepsy Disclosed is a developmental animal model of temporal lobe epilepsy and other seizure-related disorders. In particular, the invention provides a method of inducing a permanent change in the neurological development of a rodent, such as a rat, comprising daily admini...	04/25/2006
7030289	Stabilization of milk from transgenic animals The present invention relates to the stabilization of milk from transgenic animals. In particular, the invention relates to the protection of proteins (e.g. fibrinogen) expressed in milk from transgenic animals by co-expression of a serine proteinase inhibitor (e.g....	04/18/2006
7030291	CYT28 serpentine receptor disruptions, compositions and methods relating thereto The present invention relates to compositions and methods relating to the characterization and function of CYT28. Specifically, the present invention provides transgenic animals comprising disruptions in a CYT28 gene and methods of treating diseases conditions, such...	04/18/2006
7019194	SCCE modified transgenic mammals and their use as models of human disease Genetic evidence that an imbalance in the activity of serine proteases can cause severe skin disease has recently been presented. The serine protease SCCE is preferentially expressed in cornifying epithelia. Increased expression of SCCE in psoriasis has previously b...	03/28/2006
7019193	Treatments using transgenic goat produced antithrombin III This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acety...	03/28/2006
6994968	BK beta subunits of Slo family potassium channels The invention provides isolated nucleic acid and amino sequences of BK beta 2, BK beta 3, and BK beta 4, antibodies to the BK beta subunits, methods of detecting the BK beta subunits, methods of screening for modulators of Slo family potassium channels comprising BK...	02/07/2006
6987211	Transgenic non-human mammals producing a cholinesterase in their milk The present invention relates to novel alternative forms of human acetylcholinesterase (AChE) and nucleotide sequences encoding the same. The genes encoding the novel forms of human AChE have been identified in various malignant tumor cells. In a further aspect, the...	01/17/2006
6984772	Transgenic non-human mammals producing fibrinogen in their milk A transgenic, non-human mammalian animal is capable of expressing a heterologous gene for human or other recombinant physiologically functional fibrinogen holoprotein or individual subunit chain polypeptides thereof or a modified or fusion fibrinogen in mammary glan...	01/10/2006
6982361	Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal Methods and compositions for use in treating anxiety are provided. In the subject methods, an effective amount of an agent having ApoE3 activity is administered to a host suffering from an anxiety, e.g. excessive anxiety, unwanted anxiety, an anxiety disorder, etc. ...	01/03/2006
6977157	Clock gene promoter The present invention discloses a Period2 gene promoter, a construct containing the promoter and a reporter gene, a cell containing the construct, a transgenic animal harboring the construct, and a method for screening a substance which controls expression or oscill...	12/20/2005
6967076	Method for producing recombinant cells for detecting HIV Recombinant expression vectors and methods are provided for detecting HIV and monitoring HIV drug resistance. The method comprises: taking a culture of cells; adding a recombinant viral vector into the culture to transduce the cells, the recombinant viral vector com...	11/22/2005
6962688	Methods for modulation of cholesterol transport Methods for regulation of lipid and cholesterol uptake are described which are based on regulation of the expression or function of the SR-BI HDL receptor. The examples demonstrate that estrogen dramatically downregulates SR-BI under conditions of tremendous upregul...	11/08/2005
6958214	Polymorphic kinase anchor proteins and nucleic acids encoding the same Polymorphic A-kinase anchor proteins (AKAPs) and nucleic acids encoding the proteins are provided herein. Methods of detecting polymorphic AKAPs and nucleic acids encoding the AKAPs, and kits for use in the detection methods are also provided. Further provided herei...	10/25/2005
6956146	FLP-mediated gene modification in mammalian cells, and compositions and cells useful therefor A gene activation/inactivation and site-specific integration system has been developed for mammalian cells. The invention system is based on the recombination of transfected sequences by FLP, a recombinase derived from Saccharomyces. In several cell lines, FLP has b...	10/18/2005
6951740	Method for mass-production of target protein by regulating the expression of chaperone protein The present invention relates to a method for mass-production of target protein, particularly to a method for mass-production of trombopoietin by regulating the expression of chaperone protein. ...	10/04/2005
6924412	Means and methods for raising antibody concentration in compartments of the body of a non-human animal Methods and processes for raising the concentration of a first class of immunoglobulin relative to at least a second class of immunoglobulin in a compartment of the body of a non-human animal or the progeny thereof, as well as the animals produced by such methods an...	08/02/2005
6924415	Transgenic mice comprising a constitutively-activated MEK5 and exhibiting cardiac hypertrophy and dilated cardiomyopathy The present invention relates to compositions and methods relating to MEK5 and its role in heart disease. This protein has now been identified as a target for therapeutic intervention due to its role molecular events that lead to or contribute to cardiac hypertrophy...	08/02/2005
6916654	Universal donor cells Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-...	07/12/2005
6909030	PTTG knockout rodent as a model to study mechanisms for various physiological phenomena, including diabetes Disclosed is a null mutant (or knockout) rodent comprising in its germ cells an artificially induced PTTG null mutation. In some embodiments, the null mutant rodent can be generated by way of homologous recombination in an embryonic stem cell or germ cell. The inven...	06/21/2005
6906238	Effective nuclear reprogramming in mammals using CDK2 inhibitors The present invention provides methods of producing a cloned non-human mammalian nuclear transfer (NT) embryo and methods for producing a cloned non-human mammal. Embodiments of the methods include introducing donor genetic material into a metaphase I oocyte; introd...	06/14/2005
6905856	Soluble GlcNAc phosphotransferase The present invention relates to a soluble GlcNAc phosphotransferase, a method of making the same and a method of phosphorylating with the same. ...	06/14/2005
6903244	Mice which are +/− or −/− for the elastin gene as models for vascular disease Elastin, the main component of arterial extracellular matrix, was thought to have a purely structural role. Consistent with this view, elastin hemizygous mice maintain arterial extensibility by increasing the number of elastic lamellae during development. However, m...	06/07/2005
6888047	Transgenic animals as urinary bioreactors for the production of polypeptide in the urine, recombinant DNA construct for kidney-specific expression, and method of using same The invention relates to recombinant DNA constructs, a method for producing a recombinant biologically active protein in vivo in the urine of a non-human mammal using a kidney-specific promoter, such as the uromodulin promoter, and the transgenic non-human mammals t...	05/03/2005
6872868	Transgenic mammals Genetic transformation of a zygote and the embryo and mature organism which result therefrom is obtained by placing or inserting exogenous genetic material into the nucleus of the zygote or into any genetic material which ultimately forms at least a part of the nucl...	03/29/2005
6835867	Allelic series of genomic modifications in cells The present invention relates to methods of producing an allelic series of modifications in genes of interest in a cell. In particular, the invention provides methods for using nucleic acid sequence-modifying agents (e.g., chemicals, electromagnetic radiation, etc.)...	12/28/2004
6825395	Transgenic non-human mammals expressing the human complement inhibitor (DAF/CD55) This invention provides transgenic mammals other than man carrying the gene of the human complement inhibitor (DAF/CD55) and expressing the human complement inhibitor in their organs and tissues, particularly in their endothelial cells. This invention provides nonhu...	11/30/2004
6825394	Conditionally immortalized cell lines derived from transgenic animals The invention relates to mammalian cell lines and transgenic mammals. More particularly, it relates to a method for producing a rat cell line, a method for producing a transgenic rat, a transgenic rat, a rat cell line, cells and tissue obtained therefrom and uses th...	11/30/2004
6791006	LKB1 gene knockout mice A mammal is provided, in which the LKB1 gene can be deleted phase-specifically and tissue-specifically. These mammals are highly useful as tools to reveal the onset mechanism for diseases caused by LKB1 gene deficiency, such as Peutz-Jeghers syndrome and cancers, as...	09/14/2004
6781030	Methods for cloning mammals using telophase oocytes The present invention pertains to methods for cloning animals. In particular, the invention includes methods of cloning an animal by combining a genome from an activated donor cell with an activated enucleated oocyte to thereby obtain a nuclear transfer embryo, and ...	08/24/2004
6781029	Transgenic animal and methods A transgenic animal, preferably a mouse, that expresses human antichymotrypsin (ACT) in brain tissues is provided, together with animal tissue-derived cell lines and progeny animals of said transgenic animal. Progeny are obtained by mating the transgeny animal with ...	08/24/2004
6774279	Use of FLP recombinase in mice A method is disclosed for producing site-specific recombination of DNA in a transgenic non-human mammal at chromosomal regions containing Flp-recognition sites (e.g., a DNA sequence containing an FRT site). The invention in particular discloses the use of site-speci...	08/10/2004
6770797	Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid The invention features a non-transgenic model of Alzheimer's Disease, method for inducing prolonged in vivo gene expression in a mammal, and methods of inhibiting Alzheimer's Disease-associated neuronal cell death. ...	08/03/2004
6770260	Method preventing depletion of non-autologous hematopoietic cells and animal model systems for use thereof The invention provides methods for preventing depletion of non-autologous hematopoietic cells. Animal model systems using the method are also provided as are methods of treatment using non-autologous hematopoietic cells. ...	08/03/2004
6743966	Production of membrane proteins in the milk of transgenic mammals Production of proteins not normally secreted through conventional pathways such as membrane proteins including, for example, CFTR associated with cystic fibrosis, is now made possible by collection of such protein from the milk of lactating transgenic animals. ...	06/01/2004
6727405	Transgenic animals secreting desired proteins into milk A DNA sequence containing a gene encoding a protein, the gene being under the transcriptional control in the DNA sequence of a mammalian milk protein promoter which does not naturally control the transcription of the gene, such DNA sequence including DNA enabling se...	04/27/2004
6713662	Production of collagen in the milk of transgenic mammals The invention provides transgenic nonhuman mammals capable secreting exogenous procollagen or collagen into their milk. The mammals are healthy and capable of producing procollagen or collagen at high levels, usually in trimeric form. Suitable transgenes for incorpo...	03/30/2004
6706947	Method for screening for agents against cancer using an immunosuppression animal model The invention relates to an animal model of cancer. The animal carries a tumour xenograft and is immunosuppressed by administration of cyclosporin and ketoconazole. The model is useful for studying cancer and treatment thereof. ...	03/16/2004

«First «Previous 1 2 3 4 5 6 7 Next»Last»

PatentStorm

Quotables

PatentStorm News

Class 800/14 - Mammal